Trial reportEuropean journal of nuclear medicine and molecular imaging2023
[
Trial report in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Comparative Detection Performance of PSMA and Non-PSMA PET Tracers in Recurrent and Primary Prostate Cancer: A Systematic Review and Network Meta-Analysis.Clinical nuclear medicine · 2026Pooled it
- Effect ofFrontiers in medicine · 2024Pooled it
- Imaging Efficacy of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Trial
- Clinical performance of [European journal of nuclear medicine and molecular imaging · 2026Article
- Biochemical failure after radical prostatectomy with PSA ≤ 1 ng/mL: prediction of PSMA-positive metastatic disease.Annals of nuclear medicine · 2026Article
- Deep-learning-based software versus experienced nuclear medicine physician to read [European journal of nuclear medicine and molecular imaging · 2025Article
- Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer: A Systematic Review.Diagnostics (Basel, Switzerland) · 2025Review
- PSMA-based theranostics in diagnosing and treating prostate cancer in the Asian male population: a narrative review.Frontiers in oncology · 2025Review
- Article
- cfDNA fragmentation patterns correlate with tumor burden measured via PSMA PET/CT volumetric parameters in patients with biochemical recurrence of prostate cancer.EJNMMI research · 2024Article
- FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Whole-body tumour burden on [18F]DCFPyL PET/CT in biochemical recurrence of prostate cancer: association with tumour biology and PSA kinetics.European journal of nuclear medicine and molecular imaging · 2024Article
- Advancements in PSMA ligand radiolabeling for diagnosis and treatment of prostate cancer: a systematic review.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 20 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrimary objective was to compare the per-patient detection rates (DR) of [
methodsThis was a prospective, open label, cross-over, comparative study with randomized treatment administration of [
resultsA total of 205 patients with first BCR after radical prostatectomy (73%; median PSA = 0.46 ng/ml [CI 0.16;27.0]) or radiation therapy (27%; median PSA = 4.23 ng/ml [CI 1.4;98.6]) underwent [
conclusionsThe primary endpoint of this study was achieved, confirming a significantly higher detection rate for [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.